Website
N/ATelephone
1.408.720.1906
Address
480 Oakmead Parkway Sunnyvale, CA 94085
Description
EBR Systems, Inc. engages in the development of implantable systems for wireless tissue stimulation. Its WiCS Wireless Cardiac Stimulation technology helps address the significant opportunity to eliminate cardiac pacing leads. The company was founded by Richard E. Riley and Debra Sheryl Echt in 2003 and is headquartered in Sunnyvale, CA.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.59 - 1.23
Trade Value (12mth)
US$33,131.00
1 week
4.23%
1 month
2.6%
YTD
53.88%
1 year
66.81%
All time high
1.34
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
-$33m
Free Cash Flow Return
-48.70%
ROIC
-52.20%
Interest Coverage
-7.50
Quick Ratio
11.50
Shares on Issue (Fully Dilluted)
311m
HALO Sector
Healthcare
Next Company Report Date
26-Feb-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
19 December 24 |
EBR schedules Pre-Approval Inspection with the FDA
×
EBR schedules Pre-Approval Inspection with the FDA |
16 December 24 |
Notification of cessation of securities - EBR
×
Notification of cessation of securities - EBR |
13 December 24 |
Notification regarding unquoted securities - EBR
×
Notification regarding unquoted securities - EBR |
11 December 24 |
Application for quotation of securities - EBR
×
Application for quotation of securities - EBR |
06 December 24 |
EBR schedules Day-100 Meeting with the FDA
×
EBR schedules Day-100 Meeting with the FDA |
27 November 24 |
Application for quotation of securities - EBR
×
Application for quotation of securities - EBR |
27 November 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
13 November 24 |
Q3 2024 Quarterly Activity Report and Form 10-Q submission
×
Q3 2024 Quarterly Activity Report and Form 10-Q submission |
07 November 24 |
Notification of cessation of securities - EBR
×
Notification of cessation of securities - EBR |
06 November 24 |
Notification regarding unquoted securities - EBR
×
Notification regarding unquoted securities - EBR |
29 October 24 |
Form S-8 Registration Statement
×
Form S-8 Registration Statement |
25 October 24 |
Notice of Date for Q3 2024 Quarterly Report and Form 10-Q
×
Notice of Date for Q3 2024 Quarterly Report and Form 10-Q |
22 October 24 |
Substantial Holding Notification
×
Substantial Holding Notification |
17 October 24 |
Appendix 3Y
×
Appendix 3Y |
16 October 24 |
Application for quotation of securities - EBR
×
Application for quotation of securities - EBR |
16 October 24 |
EBR submits NTAP Application
×
EBR submits NTAP Application |
15 October 24 |
EBR SEC Form 3 inital director beneficial ownership filings
×
EBR SEC Form 3 inital director beneficial ownership filings |
14 October 24 |
Completion of Retail Entitlement Offer
×
Completion of Retail Entitlement Offer |
02 October 24 |
Granting of ASX waiver U.S. Financial Reporting Requirements
×
Granting of ASX waiver U.S. Financial Reporting Requirements |
30 September 24 |
FDA commences substantive review of EBR PMA application
×
FDA commences substantive review of EBR PMA application |
26 September 24 |
Cleansing Notice
×
Cleansing Notice |
25 September 24 |
Application for quotation of securities - EBR
×
Application for quotation of securities - EBR |
24 September 24 |
Retail Entitlement Offer Booklet
×
Retail Entitlement Offer Booklet |
24 September 24 |
Notification to Eligible Securityholder Letter
×
Notification to Eligible Securityholder Letter |
24 September 24 |
Notification to Ineligible Securityholder Letter
×
Notification to Ineligible Securityholder Letter |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.